Ventrus Biosciences (VTUS)
Create an AlertVentrus Biosciences Liabilities:
1.977M for March 31, 2013Ventrus Biosciences Historical Liabilities Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 1.977M |
| Dec. 31, 2012 | 2.746M |
| Sept. 30, 2012 | 2.681M |
| June 30, 2012 | 3.392M |
| March 31, 2012 | 3.853M |
| Dec. 31, 2011 | 2.513M |
| Sept. 30, 2011 | 1.183M |
| June 30, 2011 | 2.090M |
| March 31, 2011 | 1.606M |
| Dec. 31, 2010 | 2.990M |
| Sept. 30, 2010 | 17.54M |
| June 30, 2010 | 16.22M |
| March 31, 2010 | 14.92M |
| Dec. 31, 2009 | 13.53M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Note : This is a simple term, but fairly complex topic. A company's balance sheet is made up of three components : Assets, Liabilities, and Shareholder's Equity. Assets are equivalent to the sum of liabilities and shareholder's equity.
Let's say a company sells computers. The assets would be the machinery, the plant, the inventory, etc. the company. However, the value of these assets belong to who funded the company. Is the company backed by obligations/debt (loans from a bank, inventory from a supplier)? or ... The founder / common public's (shareholder's equity)? Most likely, a combination of both.
Simply, liabilities are the part of a company's assets that it has yet to repay back.
Learn More
VTUS Liabilities Benchmarks
| Companies | |
|---|---|
| Abbott Laboratories | 20.10B |
| Daiichi Sankyo | |
| Astellas Pharma |
VTUS Liabilities Rankings
| Overall |
90th percentile 1671 of 16773 |
| Sector |
88th percentile 160 of 1408 in Healthcare |
| Industry |
83rd percentile 22 of 135 in Drug Manufacturers - Major |
VTUS Liabilities Range, Past 5 Years
| Minimum | 1.183M | Sep 2011 |
| Maximum | 17.54M | Sep 2010 |
| Average | 6.232M |
